Gene Solutions, Topgen Partner to Widen Access to Molecular Cancer Tests in China

Original from: 360dx

Gene Solutions and Topgen Biomedical Technology said Thursday that they have entered a partnership under which Shaoxing, China-based Topgen will offer various genomic tests developed by Gene Solutions for cancer early detection and monitoring.

Topgen currently serves a clinical network of over 1,300 hospitals spanning 30 provinces and serving more than 100,000 patients. Under its agreement with Vietnam-headquartered Gene Solutions, Topgen will add three new tests to its existing offerings — SPOT-MAS, a multi-cancer early detection (MCED) blood test, SPOT-MAS Lung, a targeted test for lung cancer screening, and K-4CARE, a genomic and transcriptomic assay for blood-based residual disease monitoring.

SPOT-MAS (Screening for the Presence Of Tumor by DNA Methylation and Size) analyzes circulating tumor DNA for methylation patterns, fragment length variations, DNA copy number aberrations, and end motifs. Earlier this year, Gene Solutions and its collaborators published a clinical validation studyon its SPOT-MAS MCED test and noted the company's intent to commercialize its test in larger markets.

Financial terms of its deal with Topgen were not disclosed, but Topgen Board Chairman Herry Shen said in a statement that the partnership has additional value beyond an enhanced test portfolio, including joint efforts to build clinical validation data and expand into international markets.

"Topgen's robust infrastructure and clinical reach make them an ideal partner to scale our innovations," added Gene Solutions CEO Nguyen Hoai Nghia.

Source: Gene Solutions, Topgen Partner to Widen Access to Molecular Cancer Tests in China